​

Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADPT Stock Forecast

Adaptive Bio (ADPT) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $21.25, with a high of $22.00 and a low of $20.00. This represents a -4.58% decline from the last price of $22.27.

- $5 $10 $15 $20 $25 High: $22 Avg: $21.25 Low: $20 Last Closed Price: $22.27

ADPT Stock Rating

Adaptive Bio stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (64.71%), 4 Hold (23.53%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 4 11 Strong Sell Sell Hold Buy Strong Buy

ADPT Price Target Upside V Benchmarks

TypeNameUpside
StockAdaptive Bio-4.58%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts228
Avg Price Target$21.00$21.00$20.88
Last Closing Price$22.27$22.27$22.27
Upside/Downside-5.70%-5.70%-6.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26251--8
Jun, 26251--8
May, 26251--8
Apr, 26251--8
Mar, 26251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 09, 2026Morgan Stanley$20.00$20.16-0.79%-10.19%
Jun 29, 2026Guggenheim$22.00$20.964.96%-1.21%
Feb 06, 2026BTIG$22.00$16.4733.58%-1.21%
Feb 06, 2026Sebastian SandlerPiper Sandler$21.00$16.4727.50%-5.70%
Jan 26, 2026Guggenheim$21.00$18.9111.05%-5.70%
Dec 01, 2025Kallum TitchmarshMorgan Stanley$21.00$18.8411.46%-5.70%
Oct 15, 2025Piper Sandler$20.00$16.2822.85%-10.19%
Sep 30, 2025Guggenheim$20.00$13.4648.59%-10.19%
Apr 04, 2024Mark MassaroBTIG$5.00$2.6886.57%-77.55%
Dec 21, 2022David WestenbergPiper Sandler$14.00$7.0997.46%-37.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 15, 2026Cowen & Co.BuyBuyhold
Jun 29, 2026GuggenheimBuyBuyhold
Jun 17, 2026BTIGBuyBuyhold
May 06, 2026Cowen & Co.BuyBuyhold
Feb 06, 2026Cowen & Co.BuyBuyhold
Feb 06, 2026BTIGBuyBuyhold
Jan 26, 2026GuggenheimBuyBuyhold
Jan 13, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026Cowen & Co.BuyBuyhold
Oct 15, 2025Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.46$-1.00$-1.56$-1.08$-0.39-
Avg Forecast$-1.49$-1.47$-1.41$-1.12$-0.94$-0.67
High Forecast$-1.40$-1.41$-1.40$-1.11$-0.83$-0.52
Low Forecast$-1.56$-1.53$-1.44$-1.12$-1.03$-0.89
Surprise %-2.01%-31.97%10.64%-3.57%-58.51%-

Revenue Forecast

$100M $140M $180M $220M $260M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$154.34M$185.31M$170.28M$178.96M$276.98M-
Avg Forecast$152.83M$185.10M$172.93M$177.62M$210.66M$264.13M
High Forecast$158.09M$190.53M$183.72M$179.32M$216.88M$265.49M
Low Forecast$145.20M$179.67M$168.57M$174.90M$204.25M$262.77M
Surprise %0.99%0.11%-1.54%0.75%31.48%-

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-207.28M$-200.19M$-225.25M$-159.49M$-59.50M-
Avg Forecast$-232.25M$-258.20M$-225.25M$-160.99M$-141.48M$-100.85M
High Forecast$-185.80M$-206.56M$-180.20M$-159.55M$-120.32M$-74.91M
Low Forecast$-278.70M$-309.84M$-270.30M$-162.43M$-148.21M$-128.21M
Surprise %-10.75%-22.47%--0.93%-57.94%-

ADPT Forecast FAQ

Is Adaptive Bio stock a buy?

Adaptive Bio stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Adaptive Bio is a favorable investment for most analysts.

What is Adaptive Bio's price target?

Adaptive Bio's price target, set by 17 Wall Street analysts, averages $21.25 over the next 12 months. The price target range spans from $20 at the low end to $22 at the high end, suggesting a potential -4.58% change from the previous closing price of $22.27.

How does Adaptive Bio stock forecast compare to its benchmarks?

Adaptive Bio's stock forecast shows a -4.58% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Adaptive Bio over the past three months?

  • July 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Adaptive Bio’s EPS forecast?

Adaptive Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.67, marking a 71.79% increase from the reported $-0.39 in 2025..

What is Adaptive Bio’s revenue forecast?

Adaptive Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $264.13M, reflecting a -4.64% decrease from the reported $276.98M in 2025.

What is Adaptive Bio’s net income forecast?

Adaptive Bio's net income forecast for the fiscal year ending in December 2026 stands at $-101M, representing an 69.50% increase from the reported $-59.499M in 2025.